Status:
COMPLETED
Gaze Holding in Cerebellar Patients
Lead Sponsor:
University of Zurich
Conditions:
Gaze Holding in Humans
Rebound in Humans
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The long-term goal of this research is to advance the investigators knowledge of how the cerebellum a) controls gaze holding and compensates for impaired gaze stability and b) modulates vestibular inf...
Eligibility Criteria
Inclusion
- ages 18-85
- informed consent
- for group 1: acute (i.e. symptom onset \<14 days ago) cerebellar ischemia or hemorrhage as confirmed by clinical examination and brain imaging (CT or MRI)
- for group 2: chronic cerebellar degeneration as confirmed by clinical examination (presence of downbeat-nystagmus and / or gaze-evoked nystagmus and / or ataxia of gait and stance) in the absence of focal lesions (as previous cerebellar stroke, mass lesion or inflammation) on clinical routine cerebellar imaging
- absence of exclusion criteria
Exclusion
- has MRI contraindications such as pacemaker, implanted pumps, shrapnel, etc. (full MRI screening form will be filled out).
- disturbed consciousness
- other neurological or systemic disorder which can cause dementia or cognitive dysfunction
- Pregnancy or possible pregnancy if not ruled out by a negative pregnancy test.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2019
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT02185313
Start Date
August 1 2013
End Date
November 30 2019
Last Update
January 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich, Division of Neurology
Zurich, Canton of Zurich, Switzerland, 8091